USA flag logo/image

An Official Website of the United States Government

A diagnostic test for improved prostate cancer diagnosis in abnormal biopsies

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
95912
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
CA150449
Solicitation Year:
N/A
Solicitation Topic Code:
NCI
Solicitation Number:
N/A
Small Business Information
EUCLID DIAGNOSTICS, LLC
9800 Connecticut Ave Crown Point, IN 46307-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: A diagnostic test for improved prostate cancer diagnosis in abnormal biopsies
Agency: HHS
Contract: 1R43CA150449-01A1
Award Amount: $394,453.00
 

Abstract:

DESCRIPTION (provided by applicant): The overall objective of this project is to develop a prostate cancer diagnostic test for biopsies with atypical findings. Over one million prostate biopsies are performed in the US each year. Approximately 10% show abn ormalities that are suspicious but not diagnostic of cancer. These include high-grade prostatic intraepithelial neoplasia (HGPIN) and atypical small acinar proliferation (ASAP). Abnormal biopsies are a strong indicator of subsequent diagnosis of cancer. Ou r aim is to develop a diagnostic test based on DNA methylation to identify patients with abnormal biopsies who are at higher risk of a cancer diagnosis upon repeat biopsy. This test should help reduce the number of unnecessary repeat biopsies. Towards this objective, we have identified 12 novel markers that are methylated in prostate cancer. We have also developed an improved method to simultaneously detect the methylation pattern and density within a CpG island using termination-coupled linear amplificatio n (TCLA). A PCA test based on the analysis of methylated markers using TCLA should reduce the number of repeat biopsies by at least 50% and is commercially valuable as an additional tool to improve prostate cancer diagnosis. In this application, we propose to apply TCLA to detect the methylation patterns of the new markers in DNA isolated from abnormal biopsies and correlate the level of methylation to the risk of positive diagnosis on repeat biopsies. If successful, we will undertake a large validation stu dy during Phase II in preparation for a clinical trial. PUBLIC HEALTH RELEVANCE: Over one million prostate biopsies are performed each year in the US due to elevated PSA levels leading to the diagnosis of about 180,000 cases of prostate cancer. Appr oximately 10% of biopsies find abnormal cells that are indicative of cancer. The aim of this study is to develop a prostate cancer diagnostic test that can identify patients with abnormal biopsies who are at higher risk of prostate cancer diagnosis and wou ld benefit from a repeat biopsy.

Principal Investigator:

Diha J. Freije
3127380988
DIHA@EUCLIDDIAGNOSTICS.COM

Business Contact:

Igor Brikun
igor@eucliddiagnostics.com
Small Business Information at Submission:

EUCLID DIAGNOSTICS, LLC
9800 Connecticut Ave Crown Point, IN 46307

EIN/Tax ID: 120176485
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No